NYSE:DE
NYSE:DEMachinery

Is Deere (DE) Still Attractive After A 79.9% Five Year Share Price Gain?

If you are wondering whether Deere's current share price gives you a fair entry point or not, it helps to step back and look at what the valuation numbers are really saying. The stock last closed at US$514.40, with returns of 5.4% over 7 days, 6.9% over 30 days, 10.2% year to date, 14.5% over 1 year, 30.6% over 3 years and 79.9% over 5 years. This naturally raises questions about what is already reflected in the price. Recent attention on Deere has focused on its position in capital goods...
NYSE:D
NYSE:DIntegrated Utilities

Is Dominion Energy (D) Pricing Reflect Recent Offshore Wind And Asset Shift Plans?

If you are wondering whether Dominion Energy is reasonably priced or offering value at today’s levels, you are not alone. The share price recently closed at US$61.13, with returns of 5.4% over the last 7 days, 1.7% over 30 days, 3.2% year to date, 15.9% over 1 year and 5.3% over 5 years, which can change how investors think about both upside and risk. Recent news coverage has focused on how large regulated utilities like Dominion Energy are positioning their portfolios, including asset...
NYSE:CBRE
NYSE:CBREReal Estate

A Look At CBRE Group’s (CBRE) Valuation After AI Data Center Brokerage And Earnings Optimism

AI data center brokerage engagement puts CBRE in focus CBRE Group (CBRE) has drawn fresh attention after being appointed by Bitzero Holdings as real estate broker for AI focused data center capacity in Finland, alongside earnings expectations and a sector outlook described as constructive. See our latest analysis for CBRE Group. At a share price of $171.59, CBRE has recently posted a 7.24% 1 month share price return and a 25.33% 1 year total shareholder return. The latest AI data center...
NYSE:DUK
NYSE:DUKElectric Utilities

Is It Time To Reassess Duke Energy (DUK) After A Strong Five Year Run?

If you are wondering whether Duke Energy's current share price lines up with its underlying worth, you are not alone. This article is built to help you frame that question clearly. Over the last week the stock returned 2.1%, with 1.5% over the past month, 1.5% year to date, 13.1% over one year, 31.8% over three years and 60.6% over five years, which gives useful context before weighing up value. Recent coverage has focused on Duke Energy's position as a large regulated utility and ongoing...
NasdaqCM:CMPX
NasdaqCM:CMPXBiotechs

Assessing Compass Therapeutics (CMPX) Valuation After A Year Of Strong Share Price Momentum

Why Compass Therapeutics Is On Investors’ Radar Compass Therapeutics (CMPX) has drawn attention after recent share price moves, with the stock showing double digit returns over the past month and past 3 months despite reporting a net loss and no revenue. See our latest analysis for Compass Therapeutics. At a share price of $5.70, Compass Therapeutics has a 30 day share price return of 14.92% and a 90 day share price return of 33.80%. Its 1 year total shareholder return of 119.23% suggests...
NYSE:GTLS
NYSE:GTLSMachinery

Assessing Chart Industries (GTLS) Valuation As Recent Returns Offer Mixed Signals

Why Chart Industries is on investors’ radar today Chart Industries (GTLS) has recently attracted interest as investors weigh its current share price of US$207.41 against estimates of intrinsic value and recent total return figures across the past year and past 3 months. See our latest analysis for Chart Industries. While the recent 90 day share price return of 3.76% points to gradually improving momentum around the current US$207.41 level, the 1 year total shareholder return of 3.19% decline...
NasdaqGS:WWD
NasdaqGS:WWDAerospace & Defense

Assessing Woodward (WWD) Valuation After China Truck Exit And Zacks Rating Upgrade

Why Woodward’s China exit and rating upgrade matter for investors Woodward (WWD) is exiting its on-highway natural gas truck business in China after unsuccessful sale efforts, while also receiving a Zacks Rank #1 rating upgrade tied to rising earnings estimates. The China move affects a business that has not contributed meaningfully to results, and Woodward reports record fiscal 2025 sales and earnings across its Industrial and Aerospace segments, which may influence how some investors...
NYSE:RCUS
NYSE:RCUSBiotechs

Arcus’ 2026 Oncology Readouts And Phase 3 Progress Might Change The Case For Investing In RCUS

Arcus Biosciences recently outlined its 2026 priorities, highlighting multiple planned clinical data readouts for casdatifan in clear cell renal cell carcinoma and progress across its inflammation and immunology programs. The company also emphasized advancement of quemliclustat in a registrational Phase 3 trial for first-line pancreatic cancer, with results expected in the first half of 2027, underscoring a pipeline that is moving into potentially registration-enabling territory across more...
NYSE:IOT
NYSE:IOTSoftware

Fresh Broker Coverage On Samsara (IOT) Sparks A Closer Look At Its Valuation And Growth Expectations

Fresh coverage on Samsara (IOT) from several brokerages, highlighting its annual recurring revenue scale and its role in digitizing physical operations, has pushed the stock back into focus for investors assessing AI driven software names. See our latest analysis for Samsara. The latest brokerage coverage arrives after a choppy stretch, with a 1 month share price return of 8.74% decline and a 1 year total shareholder return of 25.56% decline. This contrasts with a very large 3 year total...
NasdaqGS:FROG
NasdaqGS:FROGSoftware

Is JFrog (FROG) Pricing Look Stretched After 74% One Year Share Price Jump

If you are wondering whether JFrog's current share price reflects its true worth, you are not alone. This article walks through what the numbers actually say about value. The stock most recently closed at US$56.89, with returns of a 4.0% decline over 7 days, an 11.1% decline over 30 days, a 4.5% decline year to date, a 73.7% gain over 1 year and a 143.7% return over 3 years. Those moves sit against a backdrop of ongoing investor interest in software and DevOps focused companies, where...
NYSE:PINS
NYSE:PINSInteractive Media and Services

Assessing Pinterest (PINS) Valuation After Recent Share Price Weakness And Growth Prospects

Why Pinterest (PINS) is back on investors’ radar Pinterest (PINS) has drawn fresh attention after recent share price weakness, with the stock showing negative returns over the past year and past 3 months, while revenue and value metrics offer a different snapshot of the business. See our latest analysis for Pinterest. At a share price of US$25.91, Pinterest’s recent moves include a 3 month share price return of 20% decline and a 1 year total shareholder return of 15.13% decline. This points...
NasdaqGS:SIMO
NasdaqGS:SIMOSemiconductor

A Look At Silicon Motion Technology (NasdaqGS:SIMO) Valuation After Strong Recent Share Price Momentum

Why Silicon Motion Technology (SIMO) Is Back on Investor Radar Silicon Motion Technology (SIMO) has drawn fresh attention after a strong month, with the share price moving while key fundamentals such as revenue, earnings and longer term returns provide important context for anyone tracking the stock. See our latest analysis for Silicon Motion Technology. That recent 33.5% 1 month share price return, on top of a 20.4% year to date share price gain and a 124.0% 1 year total shareholder return,...
NasdaqGS:DGII
NasdaqGS:DGIICommunications

A Look At Digi International (DGII) Valuation After New Connectivity And Network Resilience Launches

Digi International (DGII) has been active on the product front, with SmartSense ONE, Digi Ventus Managed Connectivity Solutions, and new Opengear CM8000 and OM1300 hardware expanding its presence in compliance, 5G connectivity, and network resilience. See our latest analysis for Digi International. Those product launches and Digi’s upcoming first quarter 2026 results sit against a share price of $44.05, with a 90 day share price return of 16.2% and a 1 year total shareholder return of 44.47%...
NasdaqGS:WERN
NasdaqGS:WERNTransportation

Werner Enterprises (WERN) Valuation Check After Short Term Share Price Momentum And Longer Term Weak Returns

Werner Enterprises (WERN) has drawn investor attention after a recent stretch of mixed share performance, with gains over the past month and past 3 months contrasting with weaker 1 year and multi year returns. See our latest analysis for Werner Enterprises. With the share price at US$33.14, Werner’s recent momentum appears more short term than long term, with a 90 day share price return of 19.04% contrasting with a 1 year total shareholder return decline of 7.42% and a 3 year total...
NasdaqCM:MREO
NasdaqCM:MREOBiotechs

A Look At Mereo BioPharma Group (MREO) Valuation After Mixed Setrusumab Phase 3 Results And Cash Runway Update

Mereo BioPharma Group (NasdaqCM:MREO) has come into focus after releasing mixed Phase 3 results for setrusumab in osteogenesis imperfecta, along with a cash runway update to mid-2027 and progress on its alvelestat and vantictumab programs. See our latest analysis for Mereo BioPharma Group. The mixed Phase 3 readout and cash runway update come after a volatile stretch for the stock, with a 7 day share price return of 29.45% following a 30 day share price return decline of 66.67%, and a 1 year...
NasdaqGM:DJT
NasdaqGM:DJTInteractive Media and Services

Trump Media’s Truth Social–Branded Investment Portfolios Could Be A Game Changer For Trump Media & Technology Group (DJT)

Earlier in January 2026, Trump Media & Technology Group Corp. announced four new Truth Social–branded Separately Managed Account investment strategies, offering portfolios built around industrial growth, national security, Christian values, and essential infrastructure themes, seeded with the company’s own capital. This move extends Trump Media’s reach beyond social media into branded financial products, aiming to link its America‑First messaging directly with values‑based investment options...
NYSE:UNP
NYSE:UNPTransportation

Union Pacific (UNP) Valuation Check After Recent Share Moves And Undervaluation Signals

Why Union Pacific (UNP) Is On Investors’ Radar Today Union Pacific (UNP) has drawn attention after recent share moves, with the stock showing mixed returns over the past week, month, and past 3 months while trading around $229.49 at the latest close. See our latest analysis for Union Pacific. At around $229.49, Union Pacific’s recent share price return has been soft over the past month, although its 1 year total shareholder return of 0.30% and 3 year total shareholder return of 18.00% suggest...
NasdaqGS:RIGL
NasdaqGS:RIGLBiotechs

Rigel Pharmaceuticals (RIGL) Valuation After New REZLIDHIA Trial And 2026 Revenue Guidance

Rigel Pharmaceuticals (RIGL) has drawn fresh attention after launching a Phase 1b/2 trial combining REZLIDHIA with other therapies for acute myeloid leukemia and issuing full year 2026 revenue guidance of US$275 million to US$290 million. See our latest analysis for Rigel Pharmaceuticals. Despite the latest clinical update and 2026 revenue guidance, Rigel Pharmaceuticals’ recent share price performance has cooled, with a 7 day share price return of 8.23% and a 30 day share price return of...
NYSE:MWA
NYSE:MWAMachinery

A Look At Mueller Water Products (MWA) Valuation After Passing A Peter Lynch GARP Investment Screen

Mueller Water Products triggered by GARP screen Mueller Water Products (MWA) recently passed a Peter Lynch Growth at a Reasonable Price screen, highlighting a mix of earnings growth, PEG based valuation, financial strength, and return on equity that has caught investor attention. See our latest analysis for Mueller Water Products. The GARP trigger comes after a steady run, with a 7 day share price return of 4.24% and a 30 day share price return of 6.39% at a latest close of $26.31, while 1...
NYSE:BBWI
NYSE:BBWISpecialty Retail

Did Securities Lawsuit Over Growth Missteps Just Shift Bath & Body Works' (BBWI) Investment Narrative?

Glancy Prongay & Murray LLP has filed a securities class action in the Southern District of Ohio alleging Bath & Body Works misled investors between June 4, 2024 and November 19, 2025, following sharp year-over-year declines in earnings, multiple guidance cuts, and acknowledgment that recent growth initiatives failed to expand its customer base. The lawsuit arrives as Bath & Body Works is both closing more mall locations and refreshing product lines, underscoring the tension between...
NYSE:CAVA
NYSE:CAVAHospitality

Is Cava Group (CAVA) Pricing In Too Much Growth After Its Recent Share Price Rebound

If you are wondering whether CAVA Group at around US$72 a share is a bargain or already pricing in a lot of optimism, you are not alone. The stock has returned 1.7% over the last 7 days and 35.7% over the last 30 days, while the year to date return is 19.1% and the 1 year return is a 39.0% decline. Recent coverage has focused on CAVA Group as a newly public fast casual restaurant brand with strong consumer awareness, with attention on how quickly it is expanding its store base and scaling...
NYSE:CI
NYSE:CIHealthcare

Will Cigna's (CI) New Veteran Health Initiatives Reshape Its Margin-Focused Investment Narrative?

Earlier this month, Hankook Tire America Corp. opened the Hankook Tire Clinic Powered by Evernorth at its Clarksville, Tennessee plant, while The Cigna Group also renewed its multiyear sponsorship of Achilles International’s Freedom Team with nearly US$1.00 million committed over three years. Together, these initiatives highlight Cigna’s emphasis on integrated health services and visible community investment in veterans and athletes with disabilities, reinforcing its broader health-focused...
OTCPK:PBAM
OTCPK:PBAMBanks

Private Bancorp of America PBAM Credit Quality Worsening Challenges Bullish Margin Narrative

Private Bancorp of America (PBAM) has wrapped up FY 2025 with fourth quarter revenue of US$29.9 million and basic EPS of US$1.75, alongside trailing twelve month revenue of US$119.2 million and EPS of US$7.09. Over recent periods, the company has seen quarterly revenue move from US$26.8 million in Q3 2024 to just over US$30.5 million in Q2 2025, with quarterly EPS ranging from about US$1.64 to US$1.83 over that span. This sets a clear earnings base for investors to work from. With a trailing...
NasdaqGS:BIIB
NasdaqGS:BIIBBiotechs

Biogen (BIIB) Valuation Check As High Dose Spinraza Wins Key European Approval

Biogen (BIIB) has come back into focus after the European Commission approved a high dose regimen of SPINRAZA for 5q spinal muscular atrophy, supported by Phase 2/3 DEVOTE trial results and a prior approval in Japan. See our latest analysis for Biogen. These SPINRAZA developments and Biogen's conference presence come after a choppy stretch, with a 7 day share price return of 12.37% decline and a 1 year total shareholder return of 16.98%. This suggests that longer term holders have fared...